Thyrocare Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Thyrocare Technologies wird ein jährliches Gewinn- und Umsatzwachstum von 22.8% bzw. 13.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.2% betragen.

Wichtige Informationen

22.8%

Wachstumsrate der Gewinne

22.5%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	25.7%
Wachstumsrate der Einnahmen	13.8%
Zukünftige Eigenkapitalrendite	19.2%
Analystenabdeckung	Low
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Nov 01

Recent updates

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

Jun 12

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Feb 29

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Dec 08

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 08

Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

Mar 23

Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Mar 02

Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First

Feb 01

Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%

Jan 12

The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares

Dec 24

Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive

Dec 17

Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 30

Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher

Nov 02

Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Nov 01

How Does Thyrocare Technologies Limited (NSE:THYROCARE) Fare As A Dividend Stock?

Oct 28

Insider Buying: The Thyrocare Technologies Limited (NSE:THYROCARE) Chairman Just Bought ₹20m Worth Of Shares

Oct 07

The Thyrocare Technologies (NSE:THYROCARE) Share Price Has Gained 51% And Shareholders Are Hoping For More

Sep 29

Will Thyrocare Technologies (NSE:THYROCARE) Repeat Its Return Growth Of The Past?

Sep 11

Trade Alert: The Chairman Of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Has Just Spent ₹9.6m Buying A Few More Shares

Aug 22

Thyrocare Technologies Limited's (NSE:THYROCARE) Price In Tune With Earnings

Aug 17

Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher

Jul 30

Investor Optimism Abounds Thyrocare Technologies Limited (NSE:THYROCARE) But Growth Is Lacking

Jul 28

Should Weakness in Thyrocare Technologies Limited's (NSE:THYROCARE) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jul 04

Gewinn- und Umsatzwachstumsprognosen

NSEI:THYROCARE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	7,541	1,119	1,929	1,629	1
3/31/2025	6,504	884	1,679	1,379	1
3/31/2024	5,719	708	1,060	1,676	N/A
12/31/2023	5,535	655	N/A	N/A	N/A
9/30/2023	5,468	648	647	1,418	N/A
6/30/2023	5,338	599	N/A	N/A	N/A
3/31/2023	5,267	644	857	1,293	N/A
12/31/2022	5,214	731	N/A	N/A	N/A
9/30/2022	5,108	800	749	1,001	N/A
6/30/2022	5,520	1,423	N/A	N/A	N/A
3/31/2022	5,889	1,761	756	1,134	N/A
12/31/2021	6,051	1,924	N/A	N/A	N/A
9/30/2021	6,260	2,032	1,249	1,642	N/A
6/30/2021	6,030	1,685	N/A	N/A	N/A
3/31/2021	4,946	1,132	880	1,147	N/A
12/31/2020	4,503	741	N/A	N/A	N/A
9/30/2020	4,178	692	789	1,004	N/A
6/30/2020	3,797	612	N/A	N/A	N/A
3/31/2020	4,343	884	1,580	1,679	N/A
12/31/2019	4,384	1,063	N/A	N/A	N/A
9/30/2019	4,289	990	1,305	1,436	N/A
6/30/2019	4,165	892	N/A	N/A	N/A
3/31/2019	4,039	851	601	1,003	N/A
12/31/2018	3,946	939	N/A	N/A	N/A
9/30/2018	3,822	953	N/A	N/A	N/A
6/30/2018	3,663	947	N/A	N/A	N/A
3/31/2018	3,569	933	634	1,070	N/A
12/31/2017	3,493	1,117	N/A	N/A	N/A
9/30/2017	3,359	994	N/A	N/A	N/A
6/30/2017	3,258	759	N/A	N/A	N/A
3/31/2017	3,045	428	N/A	896	N/A
12/31/2016	2,843	659	N/A	N/A	N/A
9/30/2016	2,699	601	N/A	N/A	N/A
6/30/2016	2,535	564	N/A	N/A	N/A
3/31/2016	2,411	518	N/A	678	N/A
3/31/2015	1,835	452	N/A	345	N/A
3/31/2014	1,502	462	N/A	462	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: THYROCAREDas prognostizierte Gewinnwachstum (22.8% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: THYROCAREDie Erträge des Unternehmens (22.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).

Hohe Wachstumserträge: THYROCAREEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: THYROCAREDie Einnahmen des Unternehmens (13.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).

Hohe Wachstumseinnahmen: THYROCAREDie Einnahmen des Unternehmens (13.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: THYROCAREDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.2 %).

Thyrocare Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Price target increased by 7.3% to ₹695

Price target decreased by 7.0% to ₹730

Price target decreased to ₹1,073

Price target increased to ₹1,233

Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Recent updates

Now 23% overvalued after recent price rise

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

New major risk - Revenue and earnings growth

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Price target decreased by 7.0% to ₹730

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

MD, CEO & Director recently bought ₹16m worth of stock

Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022

Price target decreased to ₹1,073

Thyrocare Technologies Limited Joins Rahul Guha as Managing Director

Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director

Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Price target increased to ₹1,233

Docon Technologies Private Limited entered into a share purchase agreement to acquire 66.11% stake in Thyrocare Technologies Limited (BSE:539871) from a group of shareholders for INR 45.5 billion.

Pharmeasy Looks to Acquire a Stake in Thyrocare

Investor sentiment improved over the past week

Upcoming dividend of ₹15.00 per share

Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020)

Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020)

Investor sentiment improved over the past week

Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

New 90-day low: ₹868

Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Revenue and earnings miss expectations

Third quarter 2021 earnings released: EPS ₹6.13 (vs ₹5.21 in 3Q 2020)

Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First

New 90-day low: ₹904

Thyrocare Technologies Limited to Report Q3, 2021 Results on Jan 30, 2021

Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%

The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares

Chairman & MD recently bought ₹6.3m worth of stock

Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive

Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Upcoming Dividend of ₹10.00 Per Share